Adding ZEN003694 to chemo for NUT cancer
Part of Cancer clinical trials.
This early-phase study tests whether adding ZEN003694 to standard chemotherapy (cisplatin/etoposide or carboplatin/paclitaxel) is safe and can help control NUT carcinoma. It enrolls people ages 12–17 and adults, including some patients whose cancer has spread or can’t be safely removed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have NUT carcinoma confirmed by a lab test on tumor tissue or blood sample (IHC, FISH, or sequencing).
- Your cancer is metastatic or can’t be fully removed with surgery (or surgery wouldn’t help much).
- You are at least 12 years old; if you’re 12–17, you must weigh at least 40 kg.
- Your body is strong enough for chemo: certain blood counts and organ tests meet the study’s minimums.
- You can swallow and keep down oral study medicine (ZEN003694 is taken by mouth).
- If you’re pregnant or breastfeeding, you can’t join; you and a partner must use reliable birth control during and after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests the safety and early signs of effectiveness of combining two anti-cancer drugs (ZEN003694 and abemaciclib) in teens and adults with metastatic or unresectable NUT carcinoma, breast cancer, and other solid tumors. It may help by finding a safer dose and whether the drug combination can shrink or control tumors that do not respond to standard treatments.
This trial tests a drug called cemiplimab for people with NUT carcinoma that has spread or cannot be removed. The drug aims to shrink tumors or slow their growth.
This Phase 1 study tests a new anti-cancer drug (ZEN003694) added to the usual chemotherapy capecitabine. It is for adults with colorectal cancer (and possibly other cancers) that has spread or cannot be removed and has continued despite prior standard treatment.
This trial studies whether adding a new anti-cancer drug (ZEN-3694) and the immunotherapy drug pembrolizumab to standard chemotherapy (nab-paclitaxel) can work better for advanced triple-negative breast cancer. It’s testing safety first (Phase 1) and, for some patients, how well the treatment controls the cancer.
This trial tests adding a targeted drug called dinutuximab to standard chemotherapy, surgery, and a stem cell transplant for children and young adults with a new diagnosis of high-risk neuroblastoma. The goal is to see if this combination helps more patients stay in remission.
This Phase 2 trial tests ZEN003694 in people with squamous (a type of) lung cancer that has returned or spread. It’s designed for tumors that have a certain gene change, and it may offer a new treatment option after prior chemotherapy and immunotherapy.
Hear when a new Metastatic NUT Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.